Moderna discusses supplying 80M doses of mRNA-1273 to EU

By The Science Advisory Board staff writers

August 24, 2020 -- Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate, as part of the commission's goal to secure early access to safe and effective COVID-19 vaccines for Europe.

The potential agreement with the commission for 80 million doses also provides an option for European Union member states to purchase an additional 80 million doses for a total of up to 160 million doses. Discussions are underway to ensure that member states will have access to the vaccine.

The phase III study of mRNA-1273, a prefusion-stabilized spike protein mRNA vaccine against SARS-CoV-2, began on July 27 and is currently enrolling a target 30,000 participants by September.

Moderna is scaling up global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year beginning in 2021. In Europe, Moderna is partnering with Lonza in Switzerland and Rovi in Spain for manufacturing and fill-finish outside of the U.S.

U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.
Amazon powers Moderna's digital biotech platform
Amazon Web Services is providing cloud, analytics, and machine-learning services to Moderna for its messenger RNA platform and manufacturing facility.
Animal study turns in positive results for Moderna-NIH COVID-19 vaccine
Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, has been shown to induce immune responses and control upper and lower respiratory tract...
Moderna begins phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately...
Moderna reports positive results in COVID-19 vaccine trial
Moderna is reporting positive results with a COVID-19 vaccine candidate it is developing. The candidate, messenger RNA (mRNA)-1273, was safe and triggered...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter